Is the MDR1 C3435T polymorphism responsible for oral mucositis in children with acute lymphoblastic leukemia?

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 10, 2012, Pages 5251-5255

  Bektas Kayhan, Kivanç ^a   Küçükhüseyin, özlem ^a   Karagöz, Gizem ^a   Ünür, Meral ^a   Öztürk, Oguz ^a   Ünüvar, Aysegül ^a   Devecioglu, ömer ^a   Yilmaz Aydogan, Hülya ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Acute lymphoblastic leukemia; MDR 1 C3435T polymorphism; Oral mucositis; Reactive oxygen species

Indexed keywords

EID: 84874003013     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.10.5251     Document Type: Article

References (37)

1. Aladjidi N, Auvrignon A, Leblanc T, et al (2003). Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of pediatric hematology and immunology. J Clin Oncol, 21, 4377-85.
2. Bradley G, Juranka PF, Ling V (1988). Mechanisms of multidrug resistance. Biochim Biophys Acta, 948, 87-128.
3. Cascorbi I, Gerloff T, Johne A, et al (2001). Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in White subjects. Clin Pharmacol Ther, 69, 169-74.
4. Chessells JM, Veys P, Kempski H, et al (2003). Long term follow-up of relapsed childhood acute lymphoblastic leukemia. Br J Haematol, 123, 396-405.
5. Chong AS, Markham PN, Gebel HM, Bines SD, Coon JS (1995). Diversemultidrugresistance-modification agents inhibit cytolytic activity of natural killer cells. Cancer Immunol Immunother, 36, 133-9.
6. Drach J, Gsur A, Hamilton G, et al (1996). Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-g in normal human T lymphocytes. Blood, 88, 1747-54.
7. Elliott JI, Raguz S, Higgins CF (2004). Multidrug transporter activity in lymphocytes. Br J Pharmacol, 143, 899-907.
8. Goldstein LJ, Galski H, Fojo A, et al (1989). Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst, 81, 116-24.
9. Greaves M (2006). Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer, 6, 193-203.
10. Gupta S, KimCH, Tsuruo T, Gollapudi S (1992). Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein), a functionally active efflux pump, in human CD8+ T cells: a role in cytotoxic effector function. J Clin Immunol, 12, 451-8.
11. Hitzl M, Drescher S, Van der Kuip H, et al (2001). The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics, 11, 293-8.
12. Hoffmeyer S, Burk O, Von Richter O, et al (2000). Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA, 97, 3473-8.
13. Illmer T, Schuler US, Thiede C, et al (2002). MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res, 62, 4955-62.
14. Jamroziak K, Mlynarski W, Balcerczak E, et al (2004). Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol, 72, 314-21.
15. Kim RB, Leake BF, Choo EF, et al (2001). Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther, 70, 189-99.
16. Kroetz DL, Pauli-Magnus C, Hodges LM, et al (2003). Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics, 13, 481-94.
17. Lin JH, Yamazaki M (2003). Role of p-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet, 42, 59-98.
18. Liscovitch M, Lavie Y (2002). Cancer multidrug resistance: a review of recent drug discovery research. IDrugs, 5, 349-55.
19. Miladpour B, Shokouhi AM, Shirdel A, et al (2009). Association of acute lymphoblastic leukemia and MDR1 gene polymorphism in an ethnic Iranian population. IJBC, 2, 63-7.
20. Miller SA, Dykes DD, Polesky HF (1998). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 16, 1215.
21. Nakamura T, Sakaeda T, Horinouchi M, et al (2002). Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther, 71, 297-303.
22. Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Kurzawski M, Gawronska-Szklarz B (2005). Involvement of C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. Eur J Pharmacol, 528, 27-36.
23. Pinto LP, Souza LB, Gordon-Nunez MA, et al (2006). Prevention of oral lesions in children with acute lymphoblastic leukemia. Int J Pediatric Otorhinolaryngol, 70, 1847-51.
24. Pui CH, Schrappe M, Ribeiro R, Niemeyer CM (2004). Childhood and adolescent lymphoid and myeloid leukemia. Hematology Am Soc Hematol Educ Program, 1, 118-45.
25. Rao DN, Anuradha C, Vishnupriya S, et al (2010). Association of an MDR1 gene (C3435T) polymorphism with acute leukemia in India. Asian Pac J Cancer Prev, 11, 1063-66.
26. Sakaeda T, Nakamura T, Okumura K (2002). MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull, 25, 1391-400.
27. Sandler DP, Ross JA (1997). Epidemiology of acute leukemia in children and adults. Semin Oncol, 24, 3-16.
28. Schinkel AH (1997). The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol, 8, 161-70.
29. Sheng X, Zhang L, Tong N, et al (2012). MDR1 C3435 T polymorphism and cancer risk: a meta-analysis based on 39 case-control studies. Mol Biol Rep, 39, 7237-49.
30. Siegsmung M, Brinkmann U, Scheffeler E, et al (2002). Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol, 13, 1847-54.
31. Sills GJ, Mohanraj R, Butler E, et al (2005). Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 46, 643-47.
32. Sonis ST (2011). Oral mucositis. Anticancer Drugs, 22, 607-12.
33. Tanabe M, Ieiri I, Nagata N, et al (2001). Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther, 297, 1137-43.
34. Urayama KY, Wiencke JK, Buffler PA, et al (2007). MDR1 gene variants, indoor insectisid exposure, and the risk of childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev, 16, 1172-7.
35. Vijayakrishnan J, Houlston RS (2010). Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Haematologica, 95, 1405-14.
36. Wang J, Wang B, Bi J, Li K, Di J (2012). MDR1 gene C3435T polymorphism and cancer risk: a meta-analysis of 39 case-control studies. J Cancer Res Clin Oncol, 138, 979-89.
37. Wartenberg M, Hoffmann E, Schwindt H, et al (2005). Reactive oxygen species-linked regulation of the multidrug resistance transporter P-glycoprotein in Nox-1 overexpressing prostate tumor spheroids. FEBS Lett, 579, 4541-9.